A cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease. The team has identified a specific estrogen receptor co-activator — known as MED1 — as playing a central role in mediating tamoxifen resistance in human breast cancer.